Ignite Creation Date:
2024-05-06 @ 10:40 AM
Last Modification Date:
2024-10-26 @ 12:34 PM
Study NCT ID:
NCT03325569
Status:
COMPLETED
Last Update Posted:
2017-10-30
First Post:
2017-10-24
Brief Title:
GLP-1 Response in Women With PCOS and Prediabetes
Sponsor:
University Medical Centre Ljubljana
Organization:
University Medical Centre Ljubljana
Study Overview
Official Title:
Reduced GLP-1 Response is Associated With Prediabetes in Women With Adverse Metabolic Phenotype of PCOS Independently of BMI
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Women with PCOS are more prone to obesity which exacerbates insulin resistance the abdominal fat disposition and metabolic risk of these patients With development of obesity these women have high conversion rate from normal glucose tolerance to impaired glucose tolerance and in turn to type 2 diabetes
Glucagon-like peptide 1 GLP-1 is involved in body weight maintenance Beside energy balance it is also involved in glucose homeostasis Functional deficit in GLP-1 facilitates obesity We investigated the link between the concentration of incretin hormones and glucose homeostasis metabolic complications and the distribution of body composition in obese women with PCOS
Glucagon-like peptide 1 GLP-1 is involved in body weight maintenance Beside energy balance it is also involved in glucose homeostasis Functional deficit in GLP-1 facilitates obesity We investigated the link between the concentration of incretin hormones and glucose homeostasis metabolic complications and the distribution of body composition in obese women with PCOS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None